Strategic Acquisitions Health Strategies Group, operating as EVERSANA, has recently expanded its capabilities through the acquisition of Waltz Health, enabling it to offer more comprehensive services in pharmacy benefit management and strengthen its position in the pharmaceutical commercialization market.

Innovative Technology Use The company's partnership with Google to implement AI-driven agency models and the launch of the EVERSANA AI Accelerator demonstrate a strong focus on leveraging cutting-edge AI solutions, creating opportunities for sales of AI and technology services to other pharma companies seeking digital transformation.

Market Leadership & Recognition consistently earns recognition, including the AI Excellence Award for three consecutive years, positioning it as a leader in commercial innovation, which can be leveraged to build credibility and trust with prospective clients looking for advanced life science services.

Broad Service Portfolio With offerings spanning global pricing, market access, patient support, and consulting, EVERSANA serves a diverse client base at various stages of the product lifecycle, opening upselling opportunities in multiple areas of pharmaceutical commercialization and patient engagement for existing and new clients.

Financial Scale and Growth Generating revenues between 100 million and 1 billion dollars with substantial funding of 18 million dollars, EVERSANA's financial strength and growth trajectory make it a compelling partner for expanding collaborations, strategic projects, and enterprise-level solutions in the pharmaceutical industry.